Risk of second breast cancer according to estrogen receptor status and family history by Bouchardy, Christine et al.
EPIDEMIOLOGY
Risk of second breast cancer according to estrogen receptor status
and family history
Christine Bouchardy • Simone Benhamou • Ge´rald Fioretta • Helena M. Verkooijen •
Pierre O. Chappuis • Isabelle Neyroud-Caspar • Monica Castiglione •
Vincent Vinh-Hung • Georges Vlastos • Elisabetta Rapiti
Received: 18 February 2010 / Accepted: 18 August 2010 / Published online: 29 September 2010
 Springer Science+Business Media, LLC. 2010
Abstract A recent study reported an increased risk of
contralateral estrogen-negative breast cancer after a first
primary estrogen-negative breast cancer. Our study aims to
confirm this result and to evaluate how the risk of second
breast cancer occurrence is affected by family history of
breast cancer and anti-estrogen treatment. We included all
4,152 women diagnosed with breast cancer between 1995
and 2007, using data from the population-based Geneva
Cancer Registry. We compared the incidence of second
breast cancer among patients according to estrogen receptor
(ER) status with that expected in the general population by
age-period Standardized Incidence Ratios (SIRs). Among
the cohort, 63 women developed second breast cancer.
Patients with ER-positive first tumors had a decreased risk of
second breast cancer occurrence (SIR: 0.67, 95% CI:
0.48–0.90), whereas patients with ER-negative primary
tumors had an increased risk (SIR: 1.98, 95% CI: 1.19–3.09)
limited to ER-negative second tumors (SIR: 7.94, 95% CI:
3.81–14.60). Patients with positive family history had a
tenfold (SIR: 9.74, 95% CI: 3.57–21.12) higher risk of ER-
negative second tumor which increased to nearly 50-fold
(SIR: 46.18, 95% CI: 12.58–118.22) when the first tumor
was ER-negative. Treatment with anti-estrogen decreased
the risk of second ER-positive tumors but not ER-negative
tumors. The risk of second ER-negative breast cancer is very
high after a first ER-negative tumor, in particular among
women with strong family history. Surveillance and pre-
vention of second cancer occurrence should consider both
ER status of the first tumor and family history.
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Introduction
Before the introduction of tamoxifen as treatment for
hormone receptor-positive tumors, approximately 15% of
breast cancer patients developed contralateral breast can-
cer, conferring a twofold increased risk compared with the
general population [1]. An Oxford meta-analysis of clinical
trials concluded that tamoxifen decreases the risk of con-
tralateral breast cancer by 43% after 5-years of treatment
[2]. However, if tamoxifen largely decreases the risk of
estrogen receptor-positive (ER) tumors, several studies
reported that it may increase the risk of developing ER-
negative tumors [3–8]. In a recent study by Li et al. [9], use
of anti-estrogen during 5 years or more was associated with
a 4.4-fold increased risk of ER-negative breast cancer.
Non-Caucasian ethnicity [10]; young age at diagnosis
[10–14]; positive family history of breast cancer [11, 14–
17]; and lobular or medullar histology [10, 11, 14, 18] have
been associated with a higher risk of contralateral breast
cancer [19–23]. Recently, Kurian et al. [24] reported that
breast cancer patients with both estrogen and progesterone
receptor-negative tumors had higher risk of developing
contralateral breast tumors, in particular hormone receptor-
negative tumors. The authors did not evaluate the effect of
family history of cancer nor anti-estrogen treatment.
In this study, we assess the risk of subsequent ER-positive
and ER-negative contralateral tumors in breast cancer
patients. In addition, we evaluated whether ER status of the
first tumor, family history of breast and/or ovarian cancer,
and use of anti-estrogens modified the association.
Patients and methods
Using data from the population-based Geneva Cancer
Registry, we identified 4,577 women diagnosed with uni-
lateral first, primary invasive breast cancer between 1995
and 2007 in the Swiss canton of Geneva. After exclusion of
patients with previous invasive cancer (except nonmel-
anoma skin cancer) (n = 328), breast cancer without his-
tological confirmation (n = 63), breast sarcoma or
lymphoma (n = 17), and breast cancer discovered at death
(n = 17), the cohort included 4,152 patients. Follow-up
was completed on December 31st 2007.
The Geneva Cancer Registry collects information from
various sources and is considered accurate, as attested by its
very low percentage (\2%) of cases recorded from death
certificates only [25]. All hospitals, pathology laboratories,
and private practitioners in the canton are requested to report
every cancer case. Trained tumor registrars systematically
extract data from medical and laboratory records, and phy-
sicians regularly receive enquiry forms to complete the
missing data.
Available data include sociodemographic information,
family history of cancer, tumor characteristics (coded
according to the International Classification of Diseases for
Oncology ICD-O) [26], hormone receptor status, and
treatment during the first 6 months after diagnosis. Socio-
economic status was based on the patient’s last occupation
or, for the unemployed, that of the spouse. Family risk was
categorized as high (at least one-first-degree relative
diagnosed with breast or ovarian cancer before the age of
50 years), none (no affected first- or second-degree relative
with breast or ovarian cancer), or moderate (all other
known family histories). ER status was classified as posi-
tive (C10% of tumor cells expressing receptors) or nega-
tive (\10% tumor cells expressing receptors). Women
were classified as never or ever user of anti-estrogen
therapy. During the study period anti-estrogen therapy
consisted mainly of tamoxifen, since aromatase inhibitors
were prescribed in Switzerland only from 2004. Accord-
ingly, we defined three periods: 1995–1999 and
2000–2004, representing the time when tamoxifen was
progressively being more prescribed, and 2005–2007,
when prescription of aromatase inhibitors began.
Definition of second breast cancer
Second breast cancers were defined as invasive primary
breast cancer occurring in the contralateral breast at least
6 months after diagnosis of the first breast cancer. For
editorial simplification we used the terms ‘‘first breast
cancer’’ instead of first primary breast cancer and ‘‘second
breast cancer’’ instead of second primary contralateral
breast cancer.
Statistical analysis
We used v2 test for heterogeneity to compare patient and
treatment characteristics between patients with ER-positive
versus ER-negative tumors.
Person-years at risk for subsequent development of
second breast cancer were computed for each woman from
6 months after the date of diagnosis of the first breast
cancer to the date of diagnosis of the second breast cancer,
date of death, date of loss to follow-up, or end of the study
period (December 31, 2007), whichever came first. The
expected number of breast cancers was calculated by
multiplying the person-years at risk (stratified by 5-year
intervals of age and calendar year) by the strata-specific
invasive breast cancer incidence rates of the female pop-
ulation of the canton of Geneva. The ratio of the observed
(O) to the expected (E) number of events denotes the
standardized incidence ratio (SIR). This SIR represents the
relative risk, adjusted for age and calendar year of devel-
oping a second breast cancer for patients diagnosed with
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first breast cancer compared with women without such a
diagnosis. We calculated 95% confidence intervals (95%
CI) of the SIRs on the basis of the assumption that the
observed number of second breast cancer followed a
Poisson distribution. All P values are two-sided and cal-
culated by Fisher exact test. SIRs were calculated for all
second breast cancers and separately for ER-positive and
ER-negative first breast cancers. Calculations of SIRs were
done with the program PYRS [27].We performed stratified
analyses by ER status of the first breast cancer, age, period
of diagnosis, and family history. We also used multivariate
Cox models to assess the independent effect of each factor
and their interaction on the risk of developing a second
breast cancer.
Results
Among the 4,152 women with breast cancer, 3,335 (80.3%)
had ER-positive, 620 (15%) had ER-negative, and 197
(4.7%) unknown ER tumor status (Table 1). Women with
ER-negative tumors were younger and often pre-meno-
pausal. ER-negative tumors were less frequently diagnosed
following screening, more often diagnosed in advanced
stages, and more often poorly differentiated. In particular,
only 16.8% of ER-negative tumors were diagnosed by
screening compared to 33.5% of ER-positive ones. ER
status was highly correlated with progesterone receptor
status and the use of anti-estrogen therapy. The proportion
of ER-negative status was similar among women with
highly increased, moderately increased, and no increased
familial risks of breast or/and ovarian cancer.
The median follow-up period was 5 years and 2 months.
The cohort yielded a total of 21,400 person-years. Between
July 1995 and December 2007, 63 second breast cancer
cases were diagnosed. Information on ER status of the first
tumor was known for 62 of these 63 cases.
Standardized incidence ratios
Overall, the risk of developing a second breast cancer
among women diagnosed with a first breast cancer of any
ER status was similar to the risk of developing a first breast
cancer in the general population (Standardized Incidence
Ratio SIR: 0.82; 95% CI: 0.62–1.02; P = 0.108) (Table 2).
Patients with ER-positive first breast cancers had a sig-
nificantly reduced risk of second breast cancers in general
(SIR: 0.67, 95% CI: 0.48–0.90), specifically ER-positive
disease (SIR: 0.55, 95% CI: 0.37–0.79). Conversely,
women with an ER-negative first breast cancer had a sig-
nificant increased risk of second breast cancer (SIR: 1.98,
95% CI: 1.19–3.09), in particular of second ER-negative
tumors (SIR: 7.94, 95% CI: 3.81–14.60) (Table 2).
Effect of age at diagnosis
Young women (\50 years) showed an overall increased
risk of developing second breast cancer (SIR: 1.79, 95%
CI: 1.08–2.80). Stratified analyses by ER status of the
second breast cancer suggest that this increased risk was
limited to ER-negative tumors (SIR: 4.12, 95% CI:
1.65–8.49). On the contrary, women C50 years old showed
an overall decreased risk of second breast cancer (SIR:
0.66, 95% CI: 0.48–0.89). When stratifying by ER status of
the second tumor, this lowered risk was limited to ER-
positive tumors (SIR: 0.49, 95% CI: 0.32–0.71).
Effect of period of diagnosis
The risk of second ER-positive breast cancer was around
0.60 for the three study periods (SIR: 0.63, 95% CI:
0.39–0.95 in 1995–1999; SIR: 0.56, 95% CI: 0.31–0.94 in
2000–2004, and SIR: 0.55, 95% CI: 0.07–1.99 in 2005–
2007). The risk of second-ER negative breast cancer was
1.10 (95% CI: 0.40–2.39) in 1995–1999, 2.18 (95% CI:
0.94–4.29) in 2000–2004, and increased to 7.76 (95% CI:
2.11–19.87) in 2005–2007.
Effect of anti-estrogen treatment
Overall, the use of anti-estrogens was associated with a
decreased risk of second ER-positive breast cancer (SIR:
0.49, 95% CI: 0.31–0.74) and had no association with
second ER-negative tumor occurrence (SIR: 1.00, 95% CI:
0.40–2.06) (Table 3). As anti-estrogens were almost
exclusively prescribed to patients with ER-positive tumors
(Table 1), we were unable to estimate their effect on sec-
ond cancer occurrence among patients with ER-negative
breast cancer.
Effect of family history
Among women without a family history of breast and/or
ovarian cancer, the risk of second breast cancer was not
significantly different for neither ER-positive second breast
cancer (SIR: 0.74, 95% CI: 0.50–1.05) nor ER-negative
second breast cancer (SIR: 1.09, 95% CI: 0.44–2.25)
(Table 4). In contrast, women with a strong family history
showed a nearly tenfold higher risk of developing an ER-
negative second tumor (SIR: 9.74, 95% CI: 3.57–21.12)
(Table 4). Analysis by ER status of the first tumor showed
that this risk was approximately 50-fold increased (SIR:
46.18, 95% CI: 12.58–118.22) when the first breast cancer
was ER-negative, and not significantly increased (SIR:
3.90, 95% CI: 0.47–14.08) among women with ER-positive
first breast cancer (Table 5).
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Table 1 Patient, tumor, and
treatment characteristics
according to ER status of the
first breast cancer
Characteristics ER status P-values*
Positive Negative Unknown
N % N % N %
N 3335 80.3 620 15.0 197 4.7
Person-years of observation 17542 2903 953
Mean age (SD) 60.4 (12.9) 56.8 (14.3) 65.9 (15.9)
Age category 0.000
\40 138 4.1 69 11.1 4 2.0
40–49 572 17.2 139 22.4 36 18.3
50–59 941 28.2 163 26.3 35 17.8
60–69 874 26.2 116 18.7 41 20.8
70–79 528 15.8 95 15.3 32 16.2
C80 282 8.5 38 6.1 49 24.9
Menopausal status 0.000
Pre- and peri-menopausal 830 24.9 228 36.8 34 17.3
Post-menopausal 2471 74.1 385 62.1 142 72.1
Unknown 34 1.0 7 1.1 21 10.7
Social class 0.138
High 490 14.7 90 14.5 28 14.2
Middle 1699 50.9 321 51.8 82 41.6
Low 514 15.4 112 18.1 33 16.8
Unknown 632 19.0 97 15.6 54 27.4
Family risk 0.862
Low 2170 65.1 413 66.6 105 53.3
Moderate 752 22.5 133 21.5 27 13.7
High 218 6.5 37 6.0 5 2.5
Unknown 195 5.8 37 6.0 60 30.5
Period of diagnosis 0.002
1995–1999 1090 32.7 248 40.0 134 68.0
2000–2004 1441 43.2 238 38.4 53 26.9
2005–2007 804 24.1 134 21.6 10 5.1
Method of detection 0.000
Screening 1116 33.5 104 16.8 22 11.2
Clinical examination 389 11.7 52 8.4 17 8.6
BSE 1279 38.4 325 52.4 46 23.4
Others 551 16.5 139 22.4 112 56.9
Stage 0.000
I 1415 42.4 173 27.9 42 21.3
II 1386 41.6 270 43.5 63 32.0
III 312 9.4 106 17.1 16 8.1
IV 131 3.9 45 7.3 31 15.7
Unknown 91 2.7 26 4.2 45 22.8
Histological subtype 0.000
Ductal 2618 78.5 525 84.7 104 52.8
Lobular 530 15.9 23 3.7 20 10.2
Other 187 5.6 72 11.6 73 37.1
Differentiation 0.000
Good 1112 33.3 30 4.8 32 16.2
Moderate 1618 48.5 180 29.0 30 15.2
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Cox models
The results of the multivariate analysis with Cox model
simultaneously adjusted for estrogen receptor, age, period,
anti-estrogen therapy, and family history are presented in
Table 6.
None of these factors had an impact on the risk of devel-
oping an ER-positive second breast cancer. ER-negative
status, most recent period of diagnosis, and strong family
history were associated with an increased risk of second ER-
negative breast cancer. In particular, the risk (Adjusted
Hazard Ratio) was 13.33 (95% CI: 2.52–70.61) for patients
diagnosed in 2005–2007 versus 1995–1999, and 9.16 (95%
CI: 3.06–27.42) for patients with strong versus no family
history risk of breast or ovarian cancer. None of the interaction
tests was significant.
Table 2 Risk of ER-positive or
ER-negative second breast
cancer occurrence according to
ER status of the first tumor
a Age period standardized
incidence ratio
b Rates are adjusted for age,
using as standard the 5-year age
distribution of the Geneva
female resident population;
rates are per 100’000 person-
years
ER estrogen receptor, CI
confidence interval, NS not
significant
Women at
risk N
Observed
cases N
Expected
cases N
SIRa (95% CI) P-values Incidence
ratesb
All first breast cancers 4152
All second breast cancers 63 76.83 0.82 (0.62–1.02) NS 294.41
Second ER? 38 63.33 0.60 (0.42–0.82) \0.05 177.58
Second ER- 18 9.63 1.87 (1.11–2.96) \0.05 84.12
Second ER unknown 7 4.17 1.68 (0.67–3.46) NS 32.71
First ER-positive 3335
All second breast cancers 43 64.18 0.67 (0.48–0.90) \0.05 245.12
Second ER? 29 52.73 0.55 (0.37–0.79) \0.05 165.31
Second ER- 8 7.92 1.01 (0.44–1.99) NS 45.60
Second ER-unknown 6 3.37 1.78 (0.65–3.86) NS 34.20
First ER-negative 620
All second breast cancers 19 9.60 1.98 (1.19–3.09) \0.05 654.46
Second ER? 8 7.84 1.02 (0.44–2.01) NS 275.56
Second ER- 10 1.26 7.94 (3.81–14.60) \0.05 344.45
Second ER-unknown 1 0.50 2.02 (0.06–11.25) NS 34.45
Table 1 continued
ER estrogen receptor; BSE
breast self-examination
* v2 of heterogeneity between
patients with ER-positive and
ER-negative tumors
Characteristics ER status P-values*
Positive Negative Unknown
N % N % N %
Poor 446 13.4 359 57.9 41 20.8
Unknown 159 4.8 51 8.2 94 47.7
Progesterone receptor status 0.000
Positive 2682 80.4 54 8.7 1 0.5
Negative 651 19.5 566 91.3 5 2.5
Unknown 2 0.1 0 191 97.0
Radiotherapy 0.957
No 821 24.6 152 24.5 144 73.1
Yes 2514 75.4 468 75.5 53 26.9
Surgery 0.353
No 239 7.2 51 8.2 96 48.7
Yes 3096 92.8 569 91.8 101 51.3
Anti-estrogen 0.000
No 499 15.0 551 88.9 119 60.4
Yes 2836 85.0 69 11.1 78 39.6
Chemotherapy 0.000
No 2160 64.8 160 25.8 151 76.6
Yes 1175 35.2 460 74.2 46 23.4
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Discussion
This study shows that the risk of developing a second
contralateral tumor after breast cancer is modified by ER
status of the first primary tumor, period of diagnosis, and
family history of breast and or ovarian cancer. In addition,
we showed that women with ER-positive tumors have a
decreased risk of developing a second ER-positive tumor,
whereas patients whose first tumor is ER-negative have an
increased risk of developing a second ER-negative tumor.
A strong family history of breast and/or ovarian cancer
further increases the risk of developing a second ER-neg-
ative tumor. In particular, patients with both ER-negative
tumors and strong family history presented a very high risk
of developing a second ER-negative tumor.
A major limitation of our study is the lack of central
pathological reviews of the breast tumors. However, in
Geneva, there are only three laboratories of cyto-
Table 3 Risk of ER-positive or
ER-negative second breast
cancer according to anti-
estrogen treatment use for the
first tumor
a Age period standardized
incidence ratio
b Rates are adjusted for age,
using as standard the 5-year age
distribution of the Geneva
female resident population;
rates are per 100’000 person-
years
ER estrogen receptor, CI
confidence interval, NS not
significant
Second breast cancer
Women at
risk N
Observed
cases N
Expected
cases N
SIRa (95% CI) P-values Incidence
ratesb
With anti-estrogen use 2983
All second breast cancers 33 56.90 0.58 (0.40–0.81) \0.05 215.21
Second ER? 23 46.94 0.49 (0.31–0.74) \0.05 149.99
Second ER- 7 7.00 1.00 (0.40–2.06) NS 45.65
Second ER-unknown 3 2.94 1.02 (0.21–2.98) NS 19.56
Without anti-estrogen use 1169
All second breast cancers 30 20.55 1.46 (0.99–1.46) NS 494.66
Second ER? 15 16.67 0.90 (0.50–1.48) NS 247.33
Second ER- 11 2.65 4.15 (2.07–7.42) \0.05 181.38
Second ER-unknown 4 1.23 3.26 (0.89–8.35) NS 65.95
Table 4 Risk of ER-positive or
ER-negative second breast
cancer according to family
history
a Age period standardized
incidence ratio
b Rates are adjusted for age,
using as standard the 5-year age
distribution of the Geneva
female resident population;
rates are per 100’000 person-
years
ER estrogen receptor, CI
confidence interval, NS not
significant
Second breast cancer
Women at
risk N
Observed
cases N
Expected
cases N
SIRa (95% CI) P value Incidence
ratesb
Family history
None 2688
All second breast cancers 41 51.25 0.80 (0.57–1.09) NS 289.29
Second ER? 31 41.89 0.74 (0.50–1.05) NS 218.73
Second ER- 7 6.42 1.09 (0.44–2.25) NS 49.39
Second ER-unknown 3 2.75 1.09 (0.23–3.19) NS 21.17
Moderate 912
All second breast cancers 11 17.46 0.63 (0.31–1.13) NS 224.73
Second ER? 4 14.29 0.28 (0.08–0.72) \0.05 81.72
Second ER- 4 2.22 1.80 (0.49–4.61) NS 81.72
Second ER-unknown 3 0.87 3.45 (0.71–10.09) NS 61.29
Strong 260
All second breast cancers 9 4.81 1.87 (0.86–3.55) NS 671.38
Second ER? 3 4 0.75 (0.16–2.19) NS 223.79
Second ER- 6 0.62 9.74 (3.57–21.12) \0.05 447.59
Second ER-unknown 0 0.22 – – – –
Unknown 292
All second breast cancers 2 3.64 0.55 (0.07–1.99) NS 201.79
Second ER? 0 2.9 – – – –
Second ER- 1 0.41 2.46 (0.07–13.70) NS 100.89
Second ER-unknown 1 0.32 3.11 (0.09–17.32) NS 100.89
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histopathology using identical quality-controlled ligand-
binding methods for the determination of receptors.
Another limitation of our study is the small number of
second breast cancers, particularly in stratified analysis by
ER status of the first tumor and family history. Therefore,
further sub-classification into ER-positive and ER-negative
second tumors yields estimates with wide confidence
intervals. The interpretation of the risk specific to second
ER-positive and second ER-negative tumors according to
the ER status of the first tumor should be made in light of
the low number of cases. Another shortcoming of the study
is the lack of information on the duration of anti-estrogen
treatment. The strength of this study is its population-based
design with prospective collection of patient and tumor
characteristics. Information on family history is accurate as
attested by its high sensitivity and specificity (98 and 97%,
respectively) in the population under study [28].
Our results are in concordance with the recent study by
Kurian et al. [24] who reported a 9.8-fold increased risk of
developing a second ER-negative tumor. Of note, in their
study, the overall risk of developing a second breast cancer
after a first hormone receptor-positive tumor was higher in
Table 5 Risk of second breast cancer according to ER status of the first tumor and family history stratified by ER status of the second tumor
Strong family history ER status of the first breast cancer
Positive Negative Unknown
Observed/
expected N
SIRa (95% CI) Observed/
expected N
SIRa (95% CI) Observed/
expected N
SIRa (95% CI)
All second breast cancers
No 39/60.0 0.65 (0.46–0.89)* 14/8.92 1.57 (0.86–2.63) 1/3.33 0.30 (0.01–1.67)
Yes 4/4.04 0.99 (0.27–2.53) 5/0.65 7.67 (2.49–17.90)* 0/0.14 –
Second breast cancer with ER-positive receptors
No 27/49.09 0.55 (0.36–0.80)* 7/7.29 0.96 (0.39–1.98) 1/2.63 0.38 (0.01–2.12)
Yes 2/3.33 0.60 (0.07–2.17) 1/0.53 1.87 (0.06–10.42) 0/11.0 –
Second breast cancer with ER-negative receptors
No 6/7.41 0.81 (0.30–1.76) 6/1.17 5.12 (1.88–11.10) 0/0.41 –
Yes 2/0.51 3.90 (0.47–14.08) 4/0.09 46.18 (12.58–118.22)* 0/0.02 –
a Age period standardized incidence ratio; * P \ 0.05; ER estrogen receptor, CI confidence interval
Table 6 Independent effect of
ER status of the first tumor, age,
period, family history, and anti-
estrogen use on second breast
cancer occurrence
a Cox model adjusted for all
variables in the table
* P \ 0.05; ** P \ 0.01;
*** P \ 0.001
ER estrogen receptor; CI
confidence interval
Characteristics Adjusted hazard ratioa (95% CI) of second breast cancer occurrence
ER? (37 events) ER- (18 events) All ER (62 events)
ER status of first tumor
Positive 1 (reference) 1 (reference) 1 (reference)
Negative 1.22 (0.46–3.25) 5.07 (1.21–21.28)* 1.66 (0.82–3.36)
Age (years)
C50 1 (reference) 1 (reference) 1 (reference)
\50 1.14 (0.55–2.39) 1.76 (0.67–4.61) 1.17 (0.67–2.05)
Period
1995–1999 1 (reference) 1 (reference) 1 (reference)
2000–2004 1.09 (0.52–2.29) 3.03 (0.83–11.0) 1.49 (0.82–2.72)
2005–2007 1.60 (0.33–7.89) 13.33 (2.52–70.61)** 4.01 (1.52–10.57)**
Family history
None 1 (reference) 1 (reference) 1 (reference)
Moderate 0.38 (0.14–1.09) 1.63 (0.48–5.59) 0.80 (0.41–1.57)
Strong 1.08 (0.33–3.55) 9.16 (3.06–27.42)*** 2.46 (1.19–5.08)*
Unknown – 2.20 (0.26–18.41) 0.77 (0.18–3.25)
Anti-estrogen use
No 1 (reference) 1 (reference) 1 (reference)
Yes 0.66 (0.28–1.55) 0.56 (0.13–2.48) 0.51 (0.26–0.99)*
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breast cancer patients than in the general population (SIR:
2.22, 95% CI: 2.15–2.29) whereas in our study, using the
same methodology, the overall risk of developing a second
breast cancer after an ER-positive tumor was lower (SIR:
0.82, 95% CI: 0.62–1.02). Exclusion of 18% of patients
with unknown data on ER status in the SEER study or
differences in the prevalence of tamoxifen use could partly
explain this difference.
The decreased risk of overall second breast cancer is
likely linked to the use of anti-estrogens among women
with ER-positive tumors. In Geneva, as compared with the
general population, the risk of second breast cancer
occurrence before the tamoxifen era in 1970–1980 was
1.58 (95% CI: 1.28–1.88) and decreased to 0.82 (95% CI:
0.62–1.02) during the study period. Our results confirm the
decrease of second breast cancer occurrence observed in
clinical trials on tamoxifen use [2].
However, as reported in previous publications, this
study also shows that tamoxifen has no effect on ER-
negative second tumor occurrence [6, 13]. A recent article
by Li et al. [9] even reported that use of tamoxifen for 5 or
more years increases the risk of second ER-negative breast
cancer. We did not observe such an effect in Geneva,
where the standard protocol used to be to prescribe
tamoxifen for 5 years.
As previously observed, young age at first breast cancer
diagnosis increases the risk of second breast cancer [1].
Our study shows that young women (\50 years) with
breast cancer are at increased risk of developing ER-neg-
ative but not ER-positive second breast cancer. However,
in multivariate analysis, age at diagnosis was no longer
significantly associated with second tumor occurrence.
A rather remarkable finding is the very strong risk of
developing second ER-negative breast cancer among
patients with strong family history, particularly when the
first tumor is ER-negative. A recent study reported that
breast cancer patients with BRCA1 or BRCA2 mutations
presented a 47% cumulative risk of developing contralat-
eral breast cancer without considering ER status neither of
the first nor of the second breast tumor [29]. ER-positive
and ER-negative breast cancers most probably differ in
terms of etiology and natural history. A recent study among
breast cancer patients diagnosed before the age of 40 years
reported that use of contraceptive pills was associated with
a fivefold increased risk of triple negative breast cancer but
had no effect on cancers with other pathological profiles
[30].
Our study also shows that the risk of second ER-nega-
tive breast cancer is particularly high for patients diagnosed
during the last study period, i.e., when aromatase inhibitors
treatment increased. In 1995–1999, 63% of women with
breast cancer included in the study received tamoxifen and
0% anti-aromatase. The corresponding proportions were 71
and 7% in 2000–2004, and 38 and 35% in 2005–2007. We
therefore hypothesize that the risk of ER-negative cancer
putatively linked to anti-aromatase could in fact be greater
than with tamoxifen.
Sensitivity of mammography is lower for ER-negative
breast cancers which are more frequently interval cancers
[31]. Our results found that ER-negative cancers are less
frequently detected by screening than ER-positive tumors
and diagnosed at more advanced stages. It is also well
documented that ER-negative tumors are more likely to be
poorly differentiated [32] as observed in this study. ER
status is a strong predictive factor by which we identify
patients who benefit from endocrine therapy. Women with
ER-negative tumors need adjuvant chemotherapy [33–35].
This study provides additional evidence on differences
between ER-positive and ER-negative breast cancers not
only in presentation, prognosis, and treatment but also in
etiology and natural history. It also provides clinicians with
information in establishing the follow-up of breast cancer
patients. Surveillance of second cancer occurrence should
be adjusted according to both ER status of the primary
breast cancer and family history of the patient. In partic-
ular, specific preventive interventions such as chemopre-
vention or prophylactic surgery should be considered for
women with both positive family history and ER-negative
first tumors. The putative increased risk of second ER-
negative tumor occurrence among patients treated with
anti-aromatase should be carefully evaluated.
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